Repligen Corporation (NASDAQ:RGEN) Receives $170.25 Consensus PT from Analysts

Shares of Repligen Corporation (NASDAQ:RGEN) have been given an average recommendation of “Moderate Buy” by the fifteen research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $169.6154.

A number of brokerages have recently issued reports on RGEN. Jefferies Financial Group restated a “hold” rating and set a $142.00 price objective on shares of Repligen in a report on Tuesday. Barclays boosted their price objective on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday. KeyCorp restated an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday. Finally, Canaccord Genuity Group reduced their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th.

Institutional Investors Weigh In On Repligen

A number of institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. boosted its holdings in shares of Repligen by 62.9% during the first quarter. PNC Financial Services Group Inc. now owns 7,271 shares of the biotechnology company’s stock worth $857,000 after acquiring an additional 2,807 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Repligen by 6.3% in the first quarter. Dimensional Fund Advisors LP now owns 854,741 shares of the biotechnology company’s stock valued at $100,681,000 after buying an additional 50,331 shares in the last quarter. KBC Group NV raised its position in shares of Repligen by 20.7% in the first quarter. KBC Group NV now owns 1,837 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 315 shares in the last quarter. Swiss National Bank raised its position in shares of Repligen by 0.4% in the first quarter. Swiss National Bank now owns 105,800 shares of the biotechnology company’s stock valued at $12,465,000 after buying an additional 400 shares in the last quarter. Finally, Roubaix Capital LLC acquired a new stake in shares of Repligen in the first quarter valued at approximately $6,428,000. Institutional investors own 97.64% of the company’s stock.

Repligen Trading Down 2.3%

Repligen stock opened at $123.46 on Friday. Repligen has a 52 week low of $109.50 and a 52 week high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.12 and a current ratio of 9.20. The stock has a market capitalization of $6.96 billion, a P/E ratio of 137.18, a PEG ratio of 2.44 and a beta of 1.09. The stock has a 50-day simple moving average of $121.00 and a 200 day simple moving average of $144.12.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The business had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter last year, the company posted $0.39 earnings per share. Repligen’s quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Analysts expect that Repligen will post 1.99 earnings per share for the current year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.